Designing a cancer therapeutic peptide by combining the mitochondrial targeting domain of Noxa and ErbB2-targeting...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Anticancer drugs often target epidermal growth factor receptors (EGFRs) to inhibit receptor tyrosine kinases and tumor proliferation.
• ErbB2 is a key target in various cancers, making it a focus for therapeutic development.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel ErbB2-targeting pronecrotic peptide, KWSY:MTD, as a potential anticancer agent.
• To investigate the mechanism of action of KWSY:MTD in ErbB2-expressing tumor cells.

Main Methods:

• In vitro studies using tumor cells expressing ErbB2.
• Assessment of cell death induction via propidium iodide uptake and HMGB1 release.
• Mitochondrial morphology analysis.
• In vivo studies using a mouse model with ErbB2-expressing tumors.

Main Results:

• KWSY:MTD selectively induced necrosis in ErbB2-expressing tumor cells in vitro.
• ErbB2 antibody inhibited KWSY:MTD-induced cell death, confirming target specificity.
• KWSY:MTD treatment led to mitochondrial swelling and release of HMGB1, indicative of necrosis.
• In vivo, KWSY:MTD partially suppressed tumor growth in mice without significant liver or kidney toxicity.

Conclusions:

• KWSY:MTD is a potent ErbB2-targeting agent that induces tumor cell necrosis.
• The peptide demonstrates selective tumor cell killing and partial tumor growth suppression in vivo.
• KWSY:MTD exhibits a favorable safety profile, suggesting its potential as an anticancer therapeutic.